Myelofibrosis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 18: Line 18:


===Treatment for Splenomegaly===
===Treatment for Splenomegaly===
*'''''JAK2'' inhibitor therapy''': Painful splenomegaly can be treated temporarily with [[ruxolitinib]].
*'''''JAK2'' inhibitor therapy''': [[ruxolitinib]] can provide temporary relief.<ref name=treatmentoverviewofmyelofibrosis1>Treatment overview of primary myelofibrosis. National cancer institute 2016. http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq#section/_9. Accessed on March 10, 2016</ref><ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>
*'''Hydroxyurea''': Hydroxyurea can reduce the splenomegaly but may have a potential leukemogenic effect.
*'''Hydroxyurea''': Hydroxyurea can reduce the splenomegaly but may have a potential leukemogenic effect.
*'''Chemotherapy''': Drugs like [[thalidomide]], [[lenalidomide]], or [[cladribine]] may reduce the spleen size, and relieve the pain symptoms associated with it.
*'''Chemotherapy''': Drugs like [[thalidomide]], [[lenalidomide]], or [[cladribine]] may also reduce the spleen size, and relieve the pain symptoms.
*'''Radiation therapy''': [[Radiation]] may be used to kill the cells and reduce the size of the spleen, when [[splenectomy]] is contraindicated.
*'''Radiation therapy''': [[Radiation]] may be used to reduce the size of the spleen, when [[splenectomy]] is contraindicated.
*'''Splenectomy''': Surgical removal of the spleen.
*'''Splenectomy''': Splenectomy can also be performed.


==References==
==References==

Revision as of 23:13, 10 December 2018

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis medical therapy

CDC on Myelofibrosis medical therapy

Myelofibrosis medical therapy in the news

Blogs on Myelofibrosis medical therapy

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Red blood cell transfusion, danazol therapy, or thalidomide are recommended for patients who develop anemia. Ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), can reduce the splenomegaly and the constitutional symptoms of weight loss, fatigue, and night sweats for patients with Janus kinase 2 (JAK2)-positive or Janus kinase 2 (JAK2)-negative primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–polycythemia vera myelofibrosis. Hydroxyurea, chemotherapy, or radiotherapy are recommended for patients who develop splenomegaly.

Medical Therapy

Treatment for Anemia

  • Red blood cell transfusion: The profound anemia that develops in this disease usually requires red blood cell transfusion.[1][2]
  • Glucocorticoids: Glucocorticoids can improve the red blood cell (RBC) survival, which can be markedly decreased in some patients.[1][3]
  • Androgen therapy: Danazol can be given to stimulate the production of red blood cells (RBCs).
  • Erythropoietic growth factors: Erythropoietin and darbepoetin can help if patients are not dependent on transfusion.
  • Thalidomide, lenalidomide, or pomalidomide: These may help in improving the red blood cell counts, thus improving anemia and help in the reversal of splenomegaly. However, patients on these drugs require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.[1][4]

Janus kinase (JAK) Inhibitor Therapy

Treatment for Splenomegaly

  • JAK2 inhibitor therapy: ruxolitinib can provide temporary relief.[1][6]
  • Hydroxyurea: Hydroxyurea can reduce the splenomegaly but may have a potential leukemogenic effect.
  • Chemotherapy: Drugs like thalidomide, lenalidomide, or cladribine may also reduce the spleen size, and relieve the pain symptoms.
  • Radiation therapy: Radiation may be used to reduce the size of the spleen, when splenectomy is contraindicated.
  • Splenectomy: Splenectomy can also be performed.

References

  1. 1.0 1.1 1.2 1.3 1.4 Treatment overview of primary myelofibrosis. National cancer institute 2016. http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq#section/_9. Accessed on March 10, 2016
  2. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  3. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  4. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  5. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  6. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.


Template:WikiDoc Sources